Cargando…
The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination
Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who receive...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427073/ https://www.ncbi.nlm.nih.gov/pubmed/36042229 http://dx.doi.org/10.1038/s41541-022-00524-7 |
_version_ | 1784778816729645056 |
---|---|
author | Goll, Johannes B. Jain, Aarti Jensen, Travis L. Assis, Rafael Nakajima, Rie Jasinskas, Algis Coughlan, Lynda Cherikh, Sami R. Gelber, Casey E. Khan, S. Huw Davies, D. Meade, Philip Stadlbauer, Daniel Strohmeier, Shirin Krammer, Florian Chen, Wilbur H. Felgner, Philip L. |
author_facet | Goll, Johannes B. Jain, Aarti Jensen, Travis L. Assis, Rafael Nakajima, Rie Jasinskas, Algis Coughlan, Lynda Cherikh, Sami R. Gelber, Casey E. Khan, S. Huw Davies, D. Meade, Philip Stadlbauer, Daniel Strohmeier, Shirin Krammer, Florian Chen, Wilbur H. Felgner, Philip L. |
author_sort | Goll, Johannes B. |
collection | PubMed |
description | Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who received 2 doses of inactivated monovalent influenza A/Indonesia/05/2005 vaccine with or without AS03 or MF59 using hemagglutinin (HA) microarrays (NCT01317758 and NCT01317745). The arrays were designed to reflect both full-length and globular head HA derived from 17 influenza A subtypes (H1 to H16 and H18) and influenza B strains. We observed significantly increased strain-specific and broad homo- and heterosubtypic antibody responses with both AS03 and MF59 adjuvanted vaccination with AS03 achieving a higher titer and breadth of IgG responses relative to MF59. The adjuvanted vaccine was also associated with the elicitation of stalk-directed antibody. We established good correlation of the array antibody responses to H5 antigens with standard HA inhibition and microneutralization titers. |
format | Online Article Text |
id | pubmed-9427073 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-94270732022-08-31 The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination Goll, Johannes B. Jain, Aarti Jensen, Travis L. Assis, Rafael Nakajima, Rie Jasinskas, Algis Coughlan, Lynda Cherikh, Sami R. Gelber, Casey E. Khan, S. Huw Davies, D. Meade, Philip Stadlbauer, Daniel Strohmeier, Shirin Krammer, Florian Chen, Wilbur H. Felgner, Philip L. NPJ Vaccines Article Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who received 2 doses of inactivated monovalent influenza A/Indonesia/05/2005 vaccine with or without AS03 or MF59 using hemagglutinin (HA) microarrays (NCT01317758 and NCT01317745). The arrays were designed to reflect both full-length and globular head HA derived from 17 influenza A subtypes (H1 to H16 and H18) and influenza B strains. We observed significantly increased strain-specific and broad homo- and heterosubtypic antibody responses with both AS03 and MF59 adjuvanted vaccination with AS03 achieving a higher titer and breadth of IgG responses relative to MF59. The adjuvanted vaccine was also associated with the elicitation of stalk-directed antibody. We established good correlation of the array antibody responses to H5 antigens with standard HA inhibition and microneutralization titers. Nature Publishing Group UK 2022-08-30 /pmc/articles/PMC9427073/ /pubmed/36042229 http://dx.doi.org/10.1038/s41541-022-00524-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Goll, Johannes B. Jain, Aarti Jensen, Travis L. Assis, Rafael Nakajima, Rie Jasinskas, Algis Coughlan, Lynda Cherikh, Sami R. Gelber, Casey E. Khan, S. Huw Davies, D. Meade, Philip Stadlbauer, Daniel Strohmeier, Shirin Krammer, Florian Chen, Wilbur H. Felgner, Philip L. The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination |
title | The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination |
title_full | The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination |
title_fullStr | The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination |
title_full_unstemmed | The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination |
title_short | The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination |
title_sort | antibody landscapes following as03 and mf59 adjuvanted h5n1 vaccination |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427073/ https://www.ncbi.nlm.nih.gov/pubmed/36042229 http://dx.doi.org/10.1038/s41541-022-00524-7 |
work_keys_str_mv | AT golljohannesb theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT jainaarti theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT jensentravisl theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT assisrafael theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT nakajimarie theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT jasinskasalgis theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT coughlanlynda theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT cherikhsamir theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT gelbercaseye theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT khans theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT huwdaviesd theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT meadephilip theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT stadlbauerdaniel theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT strohmeiershirin theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT krammerflorian theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT chenwilburh theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT felgnerphilipl theantibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT golljohannesb antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT jainaarti antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT jensentravisl antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT assisrafael antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT nakajimarie antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT jasinskasalgis antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT coughlanlynda antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT cherikhsamir antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT gelbercaseye antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT khans antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT huwdaviesd antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT meadephilip antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT stadlbauerdaniel antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT strohmeiershirin antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT krammerflorian antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT chenwilburh antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination AT felgnerphilipl antibodylandscapesfollowingas03andmf59adjuvantedh5n1vaccination |